Command Palette

Search for a command to run...

Clinical Trials · NCT04763564

Efficacy of Liraglutide Therapy in Patients With IPAA

TerminatedPhase 2Liraglutide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
University of North Carolina, Chapel Hill
Enrollment
8
Start date
Mar 2022
Locations
1 site, United States
Primary endpoint
Mean % Reduction of Bowel Frequency in Percent of the Mean 7-day Bowel Frequency After 4 Weeks of Therapy on Liraglutide vs Placebo Compared to Baseline .
View Liraglutide compound reference